Studies

The company Sanofi is currently recruiting chronic idiopathic urticaria patients for a clinical study of its new drug Dupixent in multiple sites in Canada and the US. Dupixent is already approved for use in asthma, eczema and nasal polyps.

​

If you are interested in participating, you should discuss this option with your doctor. More information on study sites and admissibility criteria is available at csutrial.com.